These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 30703220)

  • 1. Clinical Use of Dopamine Modulators as Third-Generation Antipsychotic Agents.
    Limandri BJ
    J Psychosoc Nurs Ment Health Serv; 2019 Feb; 57(2):7-11. PubMed ID: 30703220
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Third generation antipsychotic drugs: partial agonism or receptor functional selectivity?
    Mailman RB; Murthy V
    Curr Pharm Des; 2010; 16(5):488-501. PubMed ID: 19909227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanism of action of brexpiprazole: comparison with aripiprazole.
    Stahl SM
    CNS Spectr; 2016 Feb; 21(1):1-6. PubMed ID: 26899451
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [In vitro pharmacology of antipsychotics at human dopamine D2 and D3 receptors].
    Tadori Y; Kobayashi H
    Nihon Yakurigaku Zasshi; 2014 Dec; 144(6):265-71. PubMed ID: 25492361
    [No Abstract]   [Full Text] [Related]  

  • 5. Mechanism of new antipsychotic medications: occupancy is not just antagonism.
    Grunder G; Carlsson A; Wong DF
    Arch Gen Psychiatry; 2003 Oct; 60(10):974-7. PubMed ID: 14557141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pharmacology of antipsychotics at human dopamine D2 and D3 receptors].
    Tadori Y; Kikuchi T
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2012 Feb; 32(1):9-18. PubMed ID: 22568121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The antipsychotics clozapine and olanzapine increase plasma glucose and corticosterone levels in rats: comparison with aripiprazole, ziprasidone, bifeprunox and F15063.
    Assié MB; Carilla-Durand E; Bardin L; Maraval M; Aliaga M; Malfètes N; Barbara M; Newman-Tancredi A
    Eur J Pharmacol; 2008 Sep; 592(1-3):160-6. PubMed ID: 18640111
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The atypical antipsychotic, aripiprazole, blocks phencyclidine-induced disruption of prepulse inhibition in mice.
    Fejgin K; Safonov S; Pålsson E; Wass C; Engel JA; Svensson L; Klamer D
    Psychopharmacology (Berl); 2007 Apr; 191(2):377-85. PubMed ID: 17235612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pharmacology of second-generation antipsychotics: a validity of the serotonin-dopamine hypothesis].
    Kuroki T
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2004 Oct; 24(5):257-64. PubMed ID: 15658501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dissociation between in vivo occupancy and functional antagonism of dopamine D2 receptors: comparing aripiprazole to other antipsychotics in animal models.
    Natesan S; Reckless GE; Nobrega JN; Fletcher PJ; Kapur S
    Neuropsychopharmacology; 2006 Sep; 31(9):1854-63. PubMed ID: 16319908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aripiprazole: what is the role of dopamine D(2) receptor partial agonism?
    Kessler RM
    Am J Psychiatry; 2007 Sep; 164(9):1310-2. PubMed ID: 17728411
    [No Abstract]   [Full Text] [Related]  

  • 12. Aripiprazole inhibits marble-burying behavior via 5-hydroxytryptamine (5-HT)1A receptor-independent mechanisms.
    Egashira N; Okuno R; Matsushita M; Abe M; Mishima K; Iwasaki K; Nishimura R; Oishi R; Fujiwara M
    Eur J Pharmacol; 2008 Sep; 592(1-3):103-8. PubMed ID: 18644366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lumateperone: New Drug or Same Old Drug With a New Dress?
    Limandri BJ
    J Psychosoc Nurs Ment Health Serv; 2020 Jun; 58(6):9-12. PubMed ID: 32463907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dopamine D2 receptor partial agonists in the treatment of schizophrenia -example of brexpiprazole.
    Bliźniewska-Kowalska KM; Gałecki P
    Psychiatr Pol; 2024 Aug; 58(4):581-593. PubMed ID: 39378141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aripiprazole: pharmacodynamics of a dopamine partial agonist for the treatment of schizophrenia.
    Gründer G; Kungel M; Ebrecht M; Göröcs T; Modell S
    Pharmacopsychiatry; 2006 Feb; 39 Suppl 1():S21-5. PubMed ID: 16508892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serotonin receptors: their key role in drugs to treat schizophrenia.
    Meltzer HY; Li Z; Kaneda Y; Ichikawa J
    Prog Neuropsychopharmacol Biol Psychiatry; 2003 Oct; 27(7):1159-72. PubMed ID: 14642974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Partial agonist properties of the antipsychotics SSR181507, aripiprazole and bifeprunox at dopamine D2 receptors: G protein activation and prolactin release.
    Cosi C; Carilla-Durand E; Assié MB; Ormiere AM; Maraval M; Leduc N; Newman-Tancredi A
    Eur J Pharmacol; 2006 Mar; 535(1-3):135-44. PubMed ID: 16554049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study.
    Mamo D; Graff A; Mizrahi R; Shammi CM; Romeyer F; Kapur S
    Am J Psychiatry; 2007 Sep; 164(9):1411-7. PubMed ID: 17728427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Brexpiprazole: a new leaf on the partial dopamine agonist branch.
    Hope J; Castle D; Keks NA
    Australas Psychiatry; 2018 Feb; 26(1):92-94. PubMed ID: 29017334
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis.
    Kapur S; Seeman P
    Am J Psychiatry; 2001 Mar; 158(3):360-9. PubMed ID: 11229973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.